Home Archives 2009

Yearly Archives: 2009

In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s genome is sequenced and drug prescriptions are based on your genetic makeup, and argues that personalized medicine will be the defining paradigm for discovering and developing drugs of the future.

To put these videos into context, consider the recent report which found  that a majority of patients receiving Herceptin had not been tested for HER-2 overexpression — Herceptin is a targeted drug intended primarily for patients overexpressing HER-2. The apparently common prescription of Herceptin independent of it’s diagnostic test suggests that the practice of medicine needs to adapt to keep pace with scientific advance.

Vice President and Global Head of Molecular Medicine

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in September 2009


*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
FARESTONGtx Inctoremifene citrate4,696,949Sep 29, 2009
FELBATOLMeda Pharmsfelbamate4,978,680Sep 26, 2009
FELBATOLMeda Pharmsfelbamate5,082,861Sep 26, 2009
GLUCOTROL XLPfizerglipizide5,024,843Sep 5, 2009
GLUCOTROL XLPfizerglipizide5,091,190Sep 5, 2009
IMPLANONOrganon Usa Incetonogestrel5,150,718Sep 29, 2009
NEORALNovartiscyclosporine5,866,159Sep 13, 2009
NEORALNovartiscyclosporine5,916,589Sep 13, 2009
NEORALNovartiscyclosporine5,962,014Sep 13, 2009
NEORALNovartiscyclosporine5,962,017Sep 13, 2009
NEORALNovartiscyclosporine6,007,840Sep 13, 2009
NEORALNovartiscyclosporine6,024,978Sep 13, 2009
PRIMAXINMerckcilastatin sodium; imipenem5,147,868Sep 15, 2009
STARLIXNovartisnateglinideRE34878Sep 8, 2009
TOBRADEXAlcondexamethasone; tobramycin5,149,694Sep 22, 2009
TOBRADEX STAlcondexamethasone; tobramycin5,149,694Sep 22, 2009
TOBRASONEAlconfluorometholone acetate; tobramycin5,149,693Sep 22, 2009
XALATANPharmacia And Upjohnlatanoprost6,429,226Sep 6, 2009

Courtesy of DrugPatentWatch.com

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.

Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic hardships, given the direct health and indirect economic benefits of biotechnology research, will governments sustain, increase, or decrease their R&D budgets?

The impact of the global financial crisis on biotechnology development

Guest content from Naturally Obsessed

Naturally Obsessed: The Making of a Scientist

A documentary about careers in science

Naturally Obsessed

Naturally Obsessed

“So what is it that you actually do, Dr. Rifkind?” (groan, groan) It didn’t matter if the question was from my accountant, my dinner party companion or my cousin Minnie, I was never able to give an answer that satisfied either the questioner or me. That’s why, when I retired from the laboratory bench five years ago, I decided to tackle the challenge of making biomedical research more transparent.

The July 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 15, Issue 3

Editorial

The impact of the global financial crisis on biotechnology developmentPDF
Yali Friedman

Commentary

Can genetic engineering prevent food-poisoning?PDF
Henry Miller

Articles

Bottom line compliance for biotechnology: Six secretsPDF
John Avellanet
Maturation of the biotechnology industry changes job opportunities for scientistsPDF
Helen Liu, Molly B Schmid
Biotechnology business models: An Indian perspectivePDF
Viren Konde
Tracking progress: Two approaches to biotechnology development – Cases from Central EuropePDF
Tomasz Mroczkowski, Heather Elms
Umbilical cord blood banks: Modern day alchemyPDF
Helen Smith
China 10-Point Patent Checklist: Integrating patents into an overall business strategy for a Western manufacturing entity in ChinaPDF
Catherine Sun, Sharon R Barner, Harold C Wegner

From the Classroom

Bioscience enterprise: Postgraduate education at Cambridge and AucklandPDF
Linda Allan, Joerg Kistler, Chris Lowe, Wendell Dunn, Claire McGowan, Geoff Whitcher

Legal and Regulatory Updates

Legal and regulatory updatePDF
John Wilkinson

Book Reviews

Book Review: Spin-outs: Creating businesses from university intellectual propertyPDF
Arlen D Meyers
Book Review: Venture capital and the European biotechnology industryPDF
Leonard Lerer